Innovative drugs into the second half, the pharmaceutical equipment industry how to help enterprises "take the wind and waves"?

Pharmaceutical Network Market Analysis, supported by favorable policies in recent years, innovative drugs have entered the second half, is ushering in the harvest periodat the same time, with the increasing trend of aging in China, the demand for medicine gradually increased, innovative pharmaceutical industry will be rapid developmentin this context, the upstream pharmaceutical equipment industry how to help enterprises "take the wind and waves"? Pharmaceutical equipment (source: pharmaceutical network) in the next 3 years will be the domestic innovative drug market in the outbreak period of innovative drugs in terms of efficacy, safety and other significant advantages, China's pharmaceutical industry is currently showing insufficient innovation ability, innovative drugs seriously scarce situation, innovative drug research and development has become one of the key development direction sourgs in China's pharmaceutical manufacturing industryAt the same time, the, the policy has given a series of favorable support to the innovative pharmaceutical industry, including drug approval and review speed up, the state encouraged support for the development of innovative drugs and other policies, the Hong Kong Stock Exchange of China and A-share company Hasalso opened the door to listing and financing for unprofitable biopharmaceutical companiesthe number of clinical applications for innovative drugs in China has increased significantly since 2016 due to market demand and favorable policies to encourage and support innovative drugsAccording to data from the China Pharmaceutical Association, the annual number of clinical applications for class 1 chemical drugs in China in 2016 was 220, increasing to 381 in 2019, of which anti-tumor drugs accounted for 44.3%, and many varieties are in the late clinical stageit is worth mentioning that the State Drug Administration recently published three documents, such as the Breakthrough Therapeutic Drug Review Procedure (Trial), which provide detailed provisions for the review of breakthrough drugs, the review of the application for the listing of drugs with conditional conditions, and the priority review of drug market licensesindustry believes that with the refinement of the priority review of innovative drugs and breakthrough drugs, the drug review time will be further shortened, the next three years will be China's innovation drug market outbreak periodhow canupstream pharmaceutical machine industry help enterprises ride the wind and waves? In the context of the continuous development of the domestic innovative pharmaceutical industry, it will also bring a steady stream of orders and more for the vast number of development space for upstream pharmaceutical equipment enterprisesat present, international multinational companies in China's pharmaceutical equipment in the high-end market occupies a monopoly position, using its products, technology and services and other aspects of the advantages, in the high-end market has a higher market share, the price is generally higher than similar domestic productsand domestic pharmaceutical machine enterprises due to the technical level and the overall product quality is relatively low, currently mainly low-cost concentrated in the low-end marketcan be seen, the domestic pharmaceutical machine industry also has a larger market development spacewant to help innovative pharmaceutical enterprises "take the wind and waves", not to say the drug machine enterprises their own "practice" and equipment update upgrade it is understood that many domestic pharmaceutical equipment factories although marked on the product description "in line with GMP", but in fact do not understand GMP, so enterprises from the ideological understanding of the meaning of GMP, the true meaning, from practice to improve the quality of pharmaceutical equipment products industry veteranpointed pointed out that a pharmaceutical equipment meets GMP requirements, need to have several conditions: to meet the production process requirements, will not pollute drugs and production environment, easy cleaning, disinfection and sterilization, and adapt to verification needs ", "So the pharmaceutical equipment from design to manufacturing, sales of the entire process of management, need to ensure that the quality of pharmaceutical equipment to keep up with the needs of GMP development ", in addition to improving the quality of pharmaceutical equipment products, pharmaceutical companies also need to seize the new demand, new requirements of pharmaceutical companies, improve upgrade equipment for example, in terms of production capacity, improve the automation of equipment, intelligent level, to ensure production capacity, to meet the needs of enterprises high efficiency production, low-cost; take industrial boilers as an example, under the environmental protection and high pressure, industrial boilers with high energy consumption and high pollution are gradually being replaced by energy-efficient, low-emission industrial boilers, providing a good space for new boilers to develop , for pharmaceutical equipment manufacturers, the overall solution options that can support the commercialization of pharmaceutical production remain very limited pharmaceutical machine enterprises need to transition from a single equipment supplier to a solution provider conclusion, in the context of the rapid development of innovative drugs, the pharmaceutical equipment industry is facing certain opportunities and challenges domestic pharmaceutical machine enterprises need to understand the meaning of GMP, improve the quality of pharmaceutical equipment, while constantly innovation and upgrading technology, improve technology, meet the needs of pharmaceutical companies, and move towards the middle and high-end market .